嘉应制药(002198) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥94,415,395.08, a decrease of 26.52% compared to ¥128,497,088.51 in the same period last year[5] - Net profit attributable to shareholders was ¥5,182,187.84, down 57.47% from ¥12,185,969.05 year-on-year[5] - Basic and diluted earnings per share decreased by 57.50% to ¥0.0102 from ¥0.0240 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 94,415,395.08, a decrease of 26.5% compared to CNY 128,497,088.51 in the same period last year[23] - Net profit for Q1 2024 was CNY 5,182,187.84, representing a decline of 57.4% from CNY 12,185,969.05 in Q1 2023[24] Cash Flow - The net cash flow from operating activities increased significantly to ¥12,624,935.63, compared to a negative cash flow of ¥956,929.25 in the previous year, marking a 1,419.32% increase[5] - Cash inflow from operating activities totaled CNY 124,211,612.37, a decrease of 14.7% compared to CNY 145,576,648.45 in the same period last year[26] - The net cash flow from operating activities for Q1 2024 was ¥12,624,935.63, a significant improvement compared to a net outflow of ¥956,929.25 in Q1 2023, indicating a positive trend in operational efficiency[28] - Total cash outflow from operating activities amounted to ¥111,586,676.74, down from ¥146,533,577.70 in the same period last year, reflecting a reduction of approximately 24%[28] - The total cash flow for the period showed a net decrease of ¥15,003,604.08, compared to a smaller decrease of ¥1,894,311.99 in Q1 2023, highlighting a challenging cash flow environment[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥844,954,471.47, reflecting a 1.66% increase from ¥831,190,971.73 at the end of the previous year[5] - The total liabilities decreased to CNY 76,787,635.68 from CNY 84,578,465.26, reflecting a reduction of 9.2%[21] - The total assets decreased from 847,563,113.21 CNY to 844,954,471.47 CNY, a decline of about 0.3%[20] - The total liabilities include accounts payable of 12,931,493.69 CNY, which increased from 9,156,200.35 CNY, a rise of approximately 41.5%[20] Expenses - Total operating costs decreased to CNY 89,135,396.31, down 23.2% from CNY 115,949,772.87 year-on-year[23] - Sales expenses decreased by 43.35% to ¥3,303,000, primarily due to the decline in sales revenue[11] - Research and development expenses increased to CNY 2,031,024.37, up 22.5% from CNY 1,657,099.81 in Q1 2023[24] - Sales expenses significantly decreased to CNY 33,029,036.77, down 43.5% from CNY 58,301,382.66 year-on-year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 23,358[16] - The largest shareholder, Dongfang Securities Co., Ltd., holds 11.28% of shares, totaling 57,223,000 shares[16] Investments and Future Plans - The company is investing in the construction of new facilities to create additional revenue sources, which is currently progressing in an orderly manner[17] - The company plans to enhance the production capacity of its proprietary traditional Chinese medicine product, Guojin Shenrong Wan, by expanding production lines[17] - The company aims to deepen long-term cooperative relationships with partners to support the sales of Guojin Shenrong Wan[17] Accounting and Reporting - The company has not yet adopted the new accounting standards as of the beginning of 2024, which may impact future financial reporting[29] - The Q1 2024 report has not been audited, which may affect the reliability of the financial data presented[30] - The board of directors released the Q1 2024 report on April 26, 2024, indicating ongoing transparency in financial disclosures[30]